ZAI LAB LIMITED Operating Lease, Liability, Current
ZAI LAB LIMITED (ZLAB) had Operating Lease, Liability, Current of $5.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Current $5.03M.
- 2026-03-31: Operating Lease, Liability, Current $5.98M.
- 2025-12-31: Operating Lease, Liability, Current $6.34M.
- 2025-09-30: Operating Lease, Liability, Current $5.50M.
| Period end | Operating Lease, Liability, Current | Operating Lease, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.03M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.98M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $6.34M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $5.50M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.58M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $6.57M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $8.05M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $6.58M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $7.58M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $7.54M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $7.10M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $6.89M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $7.30M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $7.32M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $7.05M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $6.98M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $6.82M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $6.79M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $5.93M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $6.31M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $6.37M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $5.60M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $5.21M 10-K · filed 2022-03-01 | |
| 2020-06-30 | $4.17M 6-K · filed 2020-09-11 | |
| 2019-12-31 | $4.35M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $3.79M 6-K · filed 2020-01-21 | |
| 2019-01-01 | $2.29M 20-F · filed 2020-04-29 | $2.29M 6-K · filed 2020-01-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |